中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 5-bromo-2-(4-chlorobenzyl)-6-(4-methylphenyl)imidazo[2,1-b][1,3,4]thiadiazole | 1620897-76-8 | C18H13BrClN3S | 418.744 |
—— | 2-(4-chlorobenzyl)-6-(4-methylphenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde | 1620897-84-8 | C19H14ClN3OS | 367.859 |
—— | 2-(4-chlorobenzyl)-6-(4-methylphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl thiocyanate | 1620897-92-8 | C19H13ClN4S2 | 396.924 |
In present study, the anti-inflammatory potential of a series of 2-(4-chlorobenzyl)-5-(di(5-substituted- 1H-indol-3-yl)methyl)-6-(4-substituted phenyl)imidazo[2,1-b][1,3,4]thiadiazoles (5a-e) were evuluated after characterizing through 1H NMR, 13C NMR spectral studies. Initial toxicity and anti-inflammatory efficacy of synthesized compounds is evaluated against RAW264.7 macrophages cell line to derive at their IC50 values. Compounds 5a-e are further tested for their anti-inflammatory activity in Swiss albino rats using the 1% carrageenan-induced paw edema model. Compound 5a is taken as the lead compound and is further considered for behavioural evaluations such as stair climbing and motility exercises. Paw edema is analyzed at time intervals of 0, 1, 2, 3, 4 and 24 h and stair climbing and motility tests are surveyed after 24 h of exposure to the test compound. The results of present study show that the compound 5a significantly reduces the paw thickness by 68% at p < 0.001 and increased the stair climbing (1.5 folds) and motility (1.6 folds) when compared to the 1% carrageenan rat group. Conclusively the results of present study show that compound 5a exhibits strong anti-inflammatory potential that can be used as a preclinical template for further investigations as an alternative therapy to the current NSAIDs.